Global Acute Lung Injury Market

The Acute Lung Injury Market was valued at USD 2.85 Bn in 2024, and the total revenue of the Global Acute Lung Injury Market is expected to grow at a CAGR of 4.06% from 2025 to 2032, reaching nearly USD 3.92 Bn by 2032.

Acute Lung Injury Market Overview

Acute lung injury is a disorder of acute inflammation that destroys the endothelium and epithelial barriers of the lungs. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are forms of Respiratory Failure that have large morbidity and mortality. Recent advances are being on in studying more about the pathogenesis and treatment of ALI, but more progress is required to decrease the morbidity and mortality. The incidence of ALI depends upon factors such as Age and associated clinical disorders. Annually, the incidence of acute lung injury across the United States (1764 per 100,000 people) appears to be higher than in Europe, Australia, and other developed countries (1734 per 100,000 people). Mortality in patients with acute respiratory distress syndrome ranges from 34 to 58%.

To know about the Research Methodology :- Request Free Sample Report

The rising geriatric population, particularly in aging economies such as Japan and the United States, has contributed to higher susceptibility to respiratory illnesses, making ALI diagnosis and treatment a public health priority. Increasing pollution-related lung disorders, with the U.S. alone recording approximately 75,000 annual deaths from air pollution-related respiratory diseases, are amplifying the need for effective treatment options. Demand dynamics have shifted sharply in recent years, with mechanical ventilators and biologic therapies witnessing strong adoption as frontline treatment strategies. Mechanical ventilators remain critical in acute care settings, while biologic therapies are gaining prominence for their ability to target inflammatory pathways involved in lung injury progression. North America dominates the Acute Lung Injury Market due to its advanced healthcare infrastructure, higher public awareness, and robust reimbursement systems. The region’s strong R&D ecosystem supports rapid commercialization of new therapies.

Acute Lung Injury Market Dynamics

Growing Geriatric Population to Boost the Acute Lung Injury Market Growth

Globally, the geriatric population has increased to 16% of the total world population. It is highest in Japan, which is 28%, China at 11% and the United States has around 16% geriatric population. The prevalence of acute lung injury is highest in the geriatric population, so the growing geriatric population is a driving factor for the acute lung injury market. The mortality rate is highest in the geriatric population; therefore, it is life-threatening in the old age people.

The awareness about health is increasing among people, also due to technological advances and diagnostic advances in the medical field. It has become easier for people to get diagnosed with the diseases. The growing awareness about health diagnostics is making an important contribution to increasing the Acute Lung Injury Market growth.

The incidence of lung infections in people has increased in recent years. Pollution can be one of the major reasons for increasing lung infections and lung disorders. In Asian countries such as India, China, and Japan, the incidences are rising, and they are the emerging markets for acute lung injuries.

High Treatment Costs and Lack of Specific Diagnostics to restrains the Acute Lung Injury Market

Advanced therapies, including biologics, precision medicines, and AI-driven ventilator systems, often come with substantial expenses, making them less accessible in low- and middle-income regions. The lack of standardized, disease-specific diagnostic methods leads to delays in detection, misdiagnosis, or reliance on broad-spectrum imaging such as conventional radiography, which offers limited accuracy. The lower adoption rate of advanced imaging technologies such as digital radiography further compounds this challenge, especially in resource-constrained settings. These factors not only limit timely intervention but also hinder patient outcomes, slowing the Acute Lung Injury Market growth.

Acute Lung Injury Market Segment Analysis

Based on injury Type, the Acute Lung Injury Market is segmented into Direct Injury and Indirect injury. The direct Injury segment has having higher market share than the Indirect Injury. The Direct Injury segment currently holds the larger market share and is expected to maintain its dominance during the forecast period. Direct injuries result from conditions that cause immediate damage to lung tissues, such as pneumonia, aspiration, pulmonary contusion, and inhalation of toxic gases. These cases often require urgent and intensive medical intervention, driving demand for advanced ventilatory support, targeted drug therapies, and precision diagnostics. The high incidence of respiratory infections, pollution exposure, and occupational hazards, particularly in industrial and urban areas, further contributes to the segment’s growth. In contrast, indirect injuries, caused by systemic issues such as sepsis or severe trauma, have a relatively lower diagnosis rate in early stages, limiting their Acute Lung Injury Market share.

Based on the Therapy, the Acute Lung Injury market is segmented into pharmacotherapy, mechanical ventilation, adjunctive procedures, fluid management, and others. The Mechanical Ventilation segment dominated the Acute Lung Injury Market in 2024. Mechanical ventilation remains the primary, immediate, and most effective life-saving intervention for patients experiencing acute respiratory distress, particularly in severe ALI and Acute Respiratory Distress Syndrome (ARDS) cases. It ensures adequate oxygenation and carbon dioxide removal when the lungs are unable to function effectively, preventing multi-organ failure. Its extensive adoption in intensive care units (ICUs) worldwide is driven by well-established clinical protocols, the availability of advanced ventilator technologies, and the absence of equally effective alternative treatments. The rising incidence of critical respiratory conditions, increased hospital admissions due to infections like COVID-19, and the growing elderly population have amplified demand.

Acute Lung Injury Market Regional Insights

North America dominated the Acute Lung Injury Market in 2024 and is expected to continue its dominance over the forecast period. The strong presence of leading pharmaceutical, biotechnology, and medical device companies engaged in ALI-focused research, clinical trials, and product commercialization. The region benefits from advanced healthcare infrastructure, well-established reimbursement frameworks, and a high level of adoption of novel therapies such as biologics, inhaled corticosteroids, and AI-driven ventilator systems. the prevalence of ALI remains significant in North America due to a combination of factors, including a rising geriatric population, higher rates of chronic respiratory diseases, and the impact of pollution and lifestyle-related disorders. In the U.S. alone, tens of thousands of new ALI cases are reported annually, with many linked to sepsis, pneumonia, and trauma-related complications. The presence of major players such as Baxter International, Pfizer, and GE HealthCare—all heavily investing in precision medicine and early diagnostic solutions- strengthens the region’s market position.

The region’s rapid growth is fueled by increasing healthcare awareness, rising adoption of advanced diagnostic tools, and greater accessibility to medical devices and therapies. Factors such as urban air pollution, smoking prevalence, and the growing burden of infectious diseases like influenza, tuberculosis, and COVID-19–related lung complications have contributed to a higher incidence of Acute Lung Injury Market in countries such as India and China.

Acute Lung Injury Market Competitive Landscape

The Acute Lung Injury Market is dominated by major key players such as Baxter International Inc., Pfizer Inc., GE HealthCare Technologies Inc., Becton, Dickinson & Company, and AstraZeneca plc. Companies lead the market by their strong R&D investments, innovative product portfolios, and strategic collaborations. Baxter International focuses on advanced respiratory therapies and biologics, while Pfizer Inc. focuses its expertise in anti-inflammatory and immunomodulatory drugs to address ALI.

GE HealthCare stands out with cutting-edge ventilators and monitoring systems, and Becton, Dickinson excels in critical care devices. AstraZeneca leads with its pipeline of novel biologics targeting lung inflammation. These players maintain dominance through continuous innovation, regulatory approvals, and global distribution networks, ensuring effective ALI treatment solutions. Their emphasis on precision medicine, AI-driven diagnostics, and partnerships with academic institutions further solidifies their market position, making them the top contenders in the ALI space.

Hamilton Medical and ResMed Inc. are gaining traction with their advanced ventilator technologies tailored for acute respiratory conditions, including ALI. Novartis AG and Boehringer Ingelheim are also key innovators, focusing on anti-fibrotic and anti-inflammatory therapies to improve lung recovery.

Acute Lung Injury Market Recent Development

• GE HealthCare Technologies Inc. (United States)
October 12, 2023 – GE HealthCare announced a USD 44 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop AI-augmented point-of-care ultrasound technology aimed at improving the diagnosis and treatment of traumatic injuries and lung pathologies, including conditions linked to Acute Lung Injury (ALI). The jointly funded initiative enhances GE HealthCare’s ultrasound portfolio by integrating artificial intelligence to assist clinicians of all skill levels in rapidly identifying lung injuries, such as blast lung, as well as infectious disease-related pathologies. The advanced system features novel probes and AI-driven image interpretation to expedite trauma triage, improve decision-making, and expand access to timely care, particularly critical in mass casualty incidents when swift evaluation is essential.

• AstraZeneca plc (United Kingdom)
May 13, 2025 – The innovations in inhaled therapies, biologics, and AI-powered diagnostics. The rising geriatric population in the U.S. and Japan, coupled with pollution-related respiratory diseases causing an estimated 75,000 annual U.S. deaths, continues to fuel demand. Companies such as AstraZeneca are showcasing breakthroughs at ATS 2025, including AI-integrated lung imaging, targeted biologics like Fasenra and Tezspire, and precision inhaled therapies such as Breztri, which improve outcomes in COPD–a key ALI risk factor. GE HealthCare’s BARDA-backed AI-enhanced ultrasound aims to expedite lung injury detection in trauma and infectious disease contexts. North America leads the market due to its advanced healthcare infrastructure, while Asia Pacific is emerging rapidly, with India and China seeing rising cases.

Acute Lung Injury Market Key Trends

Acute Lung Injury Market Scope: Inquiry Before Buying

Acute Lung Injury Market, by Region

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Rest of Asia Pacific)
• Middle East and Africa (MEA) (South Africa, GCC, Nigeria, Rest of MEA)
• South America (Brazil, Argentina, Colombia, Chile, Rest of South America)

Acute Lung Injury Market, Key Players

North America
1. Baxter International Inc. (United States)
2. Pfizer Inc. (United States)
3. GE HealthCare Technologies Inc. (United States)
4. Becton, Dickinson and Company (United States)
5. Vyaire Medical Inc. (United States)
6. Hamilton Medical Inc. (United States)
7. BioMarin Pharmaceutical Inc. (United States)
8. Eli Lilly and Company (United States)

Europe
9. AstraZeneca plc (United Kingdom)
10. GlaxoSmithKline plc (United Kingdom)
11. Novartis AG (Switzerland)
12. Drägerwerk AG & Co. KGaA (Germany)
13. Smiths Medical (United Kingdom)
14. Löwenstein Medical Technology GmbH + Co. KG (Germany)
15. Boehringer Ingelheim International GmbH (Germany)

Asia Pacific
16. Terumo Corporation (Japan)
17. OMRON Healthcare, Inc. (Japan)
18. Nihon Kohden Corporation (Japan)
19. BPL Medical Technologies (India)
20. ResMed Inc. (Australia)

Middle East and Africa
21. Mansoura Medical (Egypt)
22. Biopharma Middle East FZ-LLC (UAE)

South America
23. EMS Pharma (Brazil)
24. Eurofarma Laboratórios S.A. (Brazil)
25. Libbs Farmacêutica (Brazil)

FAQ:

1] What Major Key players in the Global Acute Lung Injury Market report?
Ans. The top companies in the Acute Lung Injury Market in 2024 include Baxter International Inc., Pfizer Inc., GE HealthCare Technologies Inc., Becton, Dickinson and Company, AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, and Eli Lilly and Company.

2] Which region has the largest share in the Global Acute Lung Injury Market?
Ans. The North America region held the highest share in 2024.

3] What is the market size of the Global Acute Lung Injury Market by 2032?
Ans. The market size of the Acute Lung Injury Market by 2032 is expected to reach USD 3.92 billion.

4] What is the forecast period for the Global Acute Lung Injury Market?
Ans. The forecast period for the Global Acute Lung Injury Market is 2025-2032.

5] What was the market size of the Global Acute Lung Injury Market in 2024?
Ans. The market size of the Acute Lung Injury Market in 2024 was valued at USD 2.85 billion.